Repurposing auranofin as a drug to treat several parasitic infections

CDIPD member, Dr. Anjan Debnath, developed the first high-throughput screen for identifying drugs effective against Entamoeba histolytica. While screening a library of FDA-approved drugs and bioactives, Dr. Debnath discovered auranofin as an FDA-approved drug with better efficacy than the current treatment for amebiasis. This drug, originally developed for rheumatoid arthritis, has received Orphan Drug Status from the FDA, and is also effective against Giardia, Trichomonas, Cryptosporidium, Onchocerca and Brugia. For more details see recent press releases and publications.